Fig. 2

TET2 mRNA levels increases in CD34⁺ cells from healthy donor and MDS patients during erythropoietin-induced erythroid differentiation. TET2 expression in CD34⁺ cells from normal donors (a) and MDS patients (b) on days 6, 8 and 12 of erythroid cell differentiation, as indicated. MDS patients included in erythroid differentiation experiments were classified as refractory cytopenia with multilineage dysplasia (n = 6) and refractory anemia with ringed sideroblasts (n = 1; open circle) by WHO 2008 classification. HPRT1 was used as reference gene. Results are expressed as fold change relative to day 6 (undifferentiated cells) of culture. Horizontal lines indicate medians. The numbers of subjects studied are indicated; *p < 0.05, ANOVA and Bonferroni post hoc test